Dan Schell articles
-
A New Breed Of Generics Company
8/5/2010
I admit it — I was skeptical of the claims Alvogen was making. Prior to typing a single word on this two-year-old generics company, I encountered claims such as “creating the pharmaceutical company of tomorrow … ,” “a radical new business model … ,” and “Alvogen will be one of the world’s 10 biggest generic drugmakers by revenues in five years.”
-
Assessing Patient Recruitment Location To Improve Trial Performance
8/5/2010
Innovation, cost-effective processes, and emerging markets are probably three of the most common topics being discussed in the pharmaceutical and biopharmaceutical markets today.
-
What You Should Know About Blow-Fill-Seal Technology
7/19/2010
If you’re a U.S.-based pharmaceutical executive in charge, in any way, of manufacturing, it’s likely you haven’t seen a lot of blow-fill-seal (BFS) technology installations.
-
A Closer Look At The Business Benefits Of Clean-In-Place (CIP) Systems
7/6/2010
Malcolm McLaughlin, VP, product & business development, Alconox; and Chris Yessayan, CEO, MORK Process, answer questions about clean-in-place processes in pharma manufacturing.
-
Balancing Biotech Science And Revenue Generation
7/1/2010
A brief article from the Associated Press caught my eye today. The headline read, “Hawaii Biotech To Be Sold At Auction.” I had never heard of Hawaii Biotech, but the story intrigued me because I wondered if this was just another example of a small biotech company suffering the repercussions of a poor economy.
-
I Know The Problems. Give Me Solutions.
7/1/2010
Have you ever read the results of a research study and thought, “Well, that seems obvious”? These days, I feel that way when I read that some firm has concluded that the blockbuster model is dead, or that emerging markets are the next growth opportunity for pharma companies, or that we need to improve and accelerate our pharma/bio R&D systems and processes.
-
The Virtual Office Has Its Place
6/6/2010
There’s nothing like coming to work on a Monday morning and finding a note from the president of the company lying on your chair. Your first thought — especially if you’re not accustomed to receiving such personal correspondence — is probably, “Well, this can’t be good.” In my case, it wasn’t bad at all.
-
Finding Cost Savings In Your Everyday Business Apps
5/5/2010
I’m trying something new this month; I’m writing this column in Google Docs instead of Microsoft Word. In case you don’t know, Google Docs is essentially the search provider’s version of Microsoft Office. In other words, it includes online versions of a word processor, spreadsheet, and presentation application.
-
Is Social Networking A Waste Of Time?
4/8/2010
A colleague of mine recently questioned whether social networking was just another fad that we should ignore.
-
Building A Generics Giant
4/5/2010
She’s been with the company for 19 years, and when she started, there were about 500 employees and approximately $100 million in sales.